ArticleJournal of hematology & oncology2017

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

Ana-Alicia López-Iglesias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.